enGene

Today we’re encouraged by new preliminary results from the LEGEND trial pivotal cohort evaluating our non-viral gene therapy in non-muscle invasive bladder cancer (NMIBC), which demonstrated improved complete response rates. View the press release: engene.com/detalimogene...

We’ve proud to be recognized as one of BioSpace’s 2026 Best Places to Work, celebrating the collaborative culture that drives our innovation in non-viral genetic medicines for people with urological cancers. Learn about this achievement: engene.com/engene-named...

Hear from Kate Chan, MD, MPH, our Executive Director & Urology Clinical Lead, on Pearls & Perspectives with Amy Pearlman, MD! She discusses the challenges for high-risk NMIBC patients who fail BCG and our LEGEND trial.

Listen here: bit.ly/m/enGene

We’re proud to sponsor and attend the International Bladder Cancer Network Annual Meeting, LUGPA's Bladder & Kidney Cancer Academy and JADPRO Live events.

Swipe for conference details and connect with our team in person to learn more about our investigational, non-viral gene therapy for #NMIBC.

enGene is excited for the 3️⃣ upcoming American Urological Association meetings, where we will be highlighting encore data from our LEGEND trial, evaluating our investigational, non-viral gene therapy for patients with #NMIBC.

See below for meeting details!

Join us in welcoming this group of enGeneers! We’re thrilled to celebrate our new employees who have joined our team at a pivotal time, as we continue our mission to deliver innovative, non-viral, genetic medicine to improve the lives of people with urological cancers.

Join us in welcoming Hussein Sweiti, MD, MSc, as our Chief Medical Officer!

With 15+ years of experience and strong leadership skills, we’re confident he will be a great addition, especially as we advance our lead investigational candidate for patients with #NMIBC.

engene.com/engene-appoi...

Team enGene was proud to sponsor and attend the 15th annual Canada Walks for Bladder Cancer this #UAM25. Alongside 300+ participants, our Canadian team was proud to show up strong to raise funds with the goal of improving outcomes for every bladder cancer patient. #BCCWalk

Will you be at the South Central Section or Mid-Atlantic Section of the American Urological Association? Tune into one of several presentations from our team as we highlight the results from our ongoing LEGEND trial in patients with non-muscle invasive bladder cancer (#NMIBC).

This week, we announced our Q3 financial results and corporate updates.

Read the full update here: engene.com/engene-repor...

This week, our Co-Founder & Chief Scientific Officer, Anthony Cheung, PhD, will be presenting at #NanoThera2025. Alongside leading minds in gene therapy, he will share enGene’s unique non-viral approach—one we believe can help shape the future of care in urological cancers.

Today, Mark Preston, MD, MPH will be delivering two poster presentations at the New England Section of the American Urological Association.

Attend the sessions or visit our exhibit booth to learn more about our novel, investigational, non-viral, gene therapy for patients with #NMIBC.

#BreakingNews: Target enrollment has been achieved in the pivotal cohort of the LEGEND trial for our investigational non-viral gene therapy in #NMIBC.

Full details here: engene.com/engene-achie...

Next month, we will be presenting at three investor conferences to deliver previously disclosed information about our novel, investigational, non-viral, gene therapy for patients with #NMIBC.

Full presentation details are available here: engene.com/engene-to-pa...

We are proud to sponsor and attend the International Bladder Cancer Group Annual Retreat (#IBCG) this weekend.

Alongside fellow leaders in bladder cancer, we will join discussions on biomarkers and IBCG-BTx, sharing background on our novel, investigational, non-viral, gene therapy for #NMIBC.

We were proud to sponsor and attend the @bladdercancerus.bsky.social Think Tank during the organization’s 20th year of driving impact. Our team was honored to contribute to conversations that aim to improve quality of life for those impacted by bladder cancer.

Our CEO, Ron Cooper, is back on The Big Biz Show, discussing the latest developments at enGene and the significance of receiving the FDA’s RMAT designation for our investigational non- viral gene therapy, and what it means for the future of this disease.

We are proud to announce three promotions on our leadership team, and welcome three new members to our Board of Directors, all appointed to position our team for long-term growth at this pivotal time.

Read the full announcement: engene.com/engene-annou...

#BreakingNews: We are proud to announce that the @fda.gov has granted RMAT designation to our lead investigational therapy for patients with high-risk, non-muscle invasive bladder cancer (#NMIBC).

Read the full update here: engene.com/fda-grants-r...

Join us in welcoming the enGene summer interns!

We are honored to partner with Project Onramp, a Life Science Cares program, to support and strengthen Verose and Curtis’ experience as they launch their careers in the life science industry.

This week, enGene was awarded the @biotecanada.bsky.social 2025 Gold Leaf Award for Biotech Company of the Year.

We are proud of the recognition of our team’s ongoing pursuit to drive innovation and mainstream non-viral, gene-based immunotherapy.

Available now: Q2 financial results and business developments.

Read the full update here: engene.com/engene-repor...

The DCAT Association Summit at Lugano centers patient needs to inspire meaningful forward-thinking. This week, Anthony Cheung, PhD, Co-Founder & CSO, will be presenting an overview of our ongoing LEGEND trial in patients with #NMIBC who face high treatment burden and unmet needs.

#DCATSummit

Next week, enGene will present at the 2025 @ascocancer.bsky.social Annual Meeting, sharing our trial in progress abstract for LEGEND, our ongoing clinical study for patients with high-risk, non-muscle invasive bladder cancer (NMIBC).

We hope to see you there!

#ASCO #ASCO25

Next week, Ron Cooper, CEO, will present at the Jefferies Global Healthcare Conference, providing an overview of enGene’s scientific approach, including updates on our novel, investigational, non-viral genetic medicine for #NMIBC.

Learn more here: engene.com/engene-to-pr...

#JefferiesHealthcare

enGene is proud to welcome Amy Pott as the Chief Global Commercialization Officer. Ms. Pott joins our team at a pivotal time, as we advance the development of our lead candidate for the treatment of high-risk, #NMIBC.

Learn more: engene.com/engene-names...

This #ClinicalTrialsDay, we celebrate the passionate research and dedication driving LEGEND, our Phase 2 clinical trial for high-risk, non-muscle invasive bladder cancer (NMIBC) patients.

Learn more about the LEGEND trial here: www.thelegendstudy.com

This past weekend, we proudly participated in the Walk to End Bladder Cancer, standing in solidarity with patients, caregivers and advocates across the country.

Thank you, Bladder Cancer Advocacy Network, for organizing this impactful event.

Catch us at two key healthcare and investor conferences this month where we’ll discuss our innovative, non-viral genetic approach to addressing unmet medical needs in urological conditions like #NMIBC.

Read our press release for more information: engene.com/engene-to-pa...

#BBHIC2025

This #BladderCancerAwarenessMonth, the Bladder Cancer Advocacy Network will host walks across the country to drive awareness and fund critical research for this often-overlooked disease. We are proud to stand with BCAN and to sponsor six walks across the U.S., with our team out in force in Boston!